DBV Technologies
USUSDDBV Technologies (US:DBVTF) — Biotechnology: Biological Products (No Diagnostic Substances). Število borz, na katerih se trgujejo delnice družbe: 2. Na tej strani — cena in graf, dividende, največji imetniki in zgodovina števila delnic.
O podjetju
- Spletna stran
- dbv-technologies.com
- Odnosi z vlagatelji
- dbv-technologies.com/investor-overview/
- Sektor
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Sedež
- CHATILLON, France
- Izvršni direktor
- Mr. Daniel Tassé
- Zaposleni
- 170
- Ustanovljena
- 2002
- Delnice v obtoku
- 296.06 mio. na dan 2026-07-16
- Prosto prenosljive delnice
- 34.94 mio.
- Tržna kapitalizacija
- 731.56 mio. USD
- Notranje osebe
- 0%
- Institucionalni vlagatelji
- 41.66%
- Panoga (SIC)
- Biological Products, (No Diagnostic Substances)
- Pravna oblika
- K65D
- ISIN
- FR0010417345
- LEI
- 969500PVBQFWQKVDMD80
Opis
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Dividende
Ni bilo najdenih izplačil dividend (preverjeno 07.10.2026). Podjetje verjetno ne izplačuje dividend.
Novice ta teden
Novic s spletnega mesta podjetja še ni.
Največji imetniki
| Imetnik | Delež | Delnice | Datum poročila |
|---|---|---|---|
| MPM Bioimpact LLC | 5.83% | 3.67 mio. | 2026-06-30 |
| Siren, L.L.C. | 2.95% | 1.86 mio. | 2026-06-30 |
| Vivo Capital, LLC | 2.93% | 1.84 mio. | 2026-06-30 |
| Perceptive Advisors Llc | 2.63% | 1.65 mio. | 2026-06-30 |
| Baker Bros. Advisors, LP | 2.32% | 1.46 mio. | 2026-06-30 |
| Artisan Partners Limited… | 2.18% | 1.37 mio. | 2026-06-30 |
| UBS Group AG | 2.09% | 1.31 mio. | 2026-06-30 |
| Morgan Stanley | 1.52% | 954 908 | 2026-06-30 |
| Logos Global Management… | 1.46% | 915 000 | 2026-06-30 |
| Patient Square Capital L… | 1.45% | 909 474 | 2026-06-30 |
| Artisan Partners Funds I… | 1.34% | 840 251 | 2026-06-30 |
| Fidelity Advisor Series… | 0.68% | 428 800 | 2026-07-31 |
| MOHIDEEN PHARIS (Officer… | ≈0.23% | 144 995 | 2026-01-29 |
| RUSSELL INVESTMENT CO-Ta… | 0.07% | 45 089 | 2026-04-30 |
| RUSSELL INVESTMENT CO-U.… | 0.04% | 22 707 | 2026-04-30 |
| Fidelity Concord Street… | 0.02% | 12 855 | 2026-07-31 |
| RUSSELL INVESTMENT FUNDS… | 0.01% | 5 834 | 2026-06-30 |
| Steward Funds Inc-Stewar… | 0.01% | 4 051 | 2026-04-30 |
| LORD ABBETT SECURITIES T… | 0% | 2 973 | 2026-04-30 |
| Trust for Professional M… | 0% | 2 245 | 2026-05-31 |
| Gabelli Healthcare & Wel… | 0% | 400 | 2026-06-30 |
